AbbVie Inc. (ETR:4AB)

Market Cap	331.75B +12.7%
Revenue (ttm)	50.83B +7.4%
Net Income	2.00B -53.4%
EPS	1.13 -54.0%
Shares Out	n/a
PE Ratio	165.78
Forward PE	16.95
Dividend	5.75 (3.09%)
Ex-Dividend Date	Jan 16, 2026

Volume	554
Average Volume	490
Open	189.20
Previous Close	186.40
Day's Range	188.60 - 189.40
52-Week Range	147.60 - 207.00
Beta	0.35
RSI	45.94
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 4AB

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD